Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Ag Ord (OP: BAYZF )

28.97 -0.31 (-1.05%)
Streaming Delayed Price Updated: 2:07 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,788
Open 29.07
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 29.28
Today's Range 28.97 - 29.07
52wk Range 27.41 - 66.66
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential... 
Via Benzinga
Exposures Product Safety
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Glyphosate Legal

Performance

YTD
-23.28%
-23.28%
1 Month
-0.75%
-0.75%
3 Month
-17.51%
-17.51%
6 Month
-33.26%
-33.26%
1 Year
-56.40%
-56.40%

More News

Read More
Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
Via Benzinga
What's Going On With BridgeBio Pharma Stock On Monday?
Via Benzinga
Exposures Product Safety
Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial
Via Benzinga
Topics Lawsuit
Exposures Financial Glyphosate Legal
Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout
Via Benzinga
Exposures Glyphosate
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
Via Benzinga
Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
Via Benzinga
Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial
Via Benzinga
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
Via Benzinga
Topics Lawsuit
Exposures Financial Glyphosate Legal
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
Via Benzinga
Topics Climate Change
Exposures Climate
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
Via Benzinga
Exposures Glyphosate
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
Via Benzinga
Topics Lawsuit
Exposures Financial Glyphosate Legal
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
Via Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Via Benzinga
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
Via Benzinga
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
Via Benzinga
Exposures Glyphosate
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Via Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
Via Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
Via Benzinga
Exposures Product Safety
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
Via Benzinga
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.